Pierre Vanden Borre - Concepedia

Concepedia

Author

Pierre Vanden Borre

Boston Medical Center ORCID

Also Known As

P Vanden Borre, P. Vanden Borre, Pierre Vanden Borre

47

Publications

1.1K

Citations

14

H-Index

21

Concepts

All Affiliations

Boston Medical Center Harvard University Foundation Medicine (United States)Massachusetts General Hospital Boston University

PV

About

Pierre Vanden Borre is an author at Boston Medical Center specializing in cell biology, medicine, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	199
2	Cell Biology	4	4	199
3	Natural Sciences	1	1	22
4	Immunology	1	1	100
5	Molecular Biology	1	1	22

Pierre Vanden Borre

×

14

Publications

1.1K

Citations

14

H-Index

	Year	Citations
Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers Nikita Pozdeyev, Laurie M. Gay, Ethan Sokol, Clinical Cancer Research	2018	512
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer Ryan J. Hartmaier, Sally E. Trabucco, Nolan Priedigkeit, Annals of Oncology	2018	101
Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer Eran Brauner, Viswanath Gunda, Pierre Vanden Borre, Oncotarget ImmunologyImmunotherapyAnti Tumor ImmunityTumor BiologyTumor Immunology	2016	100
Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions Pierre Vanden Borre, Alexa B. Schrock, Peter M. Anderson, The Oncologist	2017	79
AND‐34/BCAR3 differs from other NSP homologs in induction of anti‐estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphology Richard I. Near, Yujun Zhang, Anthony Makkinje, Journal of Cellular Physiology Breast OncologyCancer BiologyMammary Gland DevelopmentD1 Promoter ActivationBinding-partner P130cas/bcar1	2007	49
Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways Viswanath Gunda, Octavian Bucur, J. Varnau, Cell Death and Disease	2014	49
Combined BRAFV600E- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer Pierre Vanden Borre, Viswanath Gunda, David G. McFadden, Oncotarget	2014	43
Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types Pashtoon Murtaza Kasi, Jessica Lee, Lincoln W. Pasquina, Clinical Cancer Research	2023	41
The Next Generation of Orthotopic Thyroid Cancer Models: Immunocompetent Orthotopic Mouse Models of BRAF <sup>V600E</sup> -Positive Papillary and Anaplastic Thyroid Carcinoma Pierre Vanden Borre, David G. McFadden, Viswanath Gunda, Thyroid	2013	38
AND-34/BCAR3 regulates adhesion-dependent p130Cas serine phosphorylation and breast cancer cell growth pattern Anthony Makkinje, Richard I. Near, Giuseppe Infusini, Cellular Signalling Tumor BiologySignaling PathwayMedicineBreast CancerTumor Suppressor	2009	28

Page 1